No title
Background: Tumour-infiltrating lymphocytes (TILs) that persist in chronic infections gradually lose their effector functions and become “exhausted”. Immune checkpoint blockade is an emerging cancer treatment which aims to induce exhausted TILs into regaining their effector function to fight neoplastic cells. However, response to treatment varies significantly between different cancer types and ma
